If You Invested in Greenland Mines Ltd (GRML)

Greenland Mines Ltd. is a Nasdaq-listed operating company with activities in natural resources and cell and gene therapy. The company's natural resources division is focused on the exploration and development of the Skaergaard Project in Southeast Greenland, a palladium, gold, platinum, and critical metals project. Its cell and gene therapy division includes Klotho-related programs, including KLTO-202 with a primary indication in ALS.

The company's current public profile reflects a corporate transformation from its former identity as Klotho Neurosciences, Inc. to Greenland Mines Ltd. Recent company materials identify two operating divisions: Natural Resources and Cell and Gene Therapy. The Natural Resources division holds its Skaergaard interest through the company's Greenlandic subsidiary, Major Precious Greenland A/S, which is described as 80%-owned. Company materials state that Greenland Mines holds an 80% interest in Skaergaard and an option to acquire the remaining 20%.

The Skaergaard Project is located in East Greenland and is described by the company as one of the largest undeveloped palladium, gold, and platinum deposits in the world. The project hosts a 2022 NI 43-101 mineral resource that company materials describe as 11.4 million ounces palladium equivalent indicated and 14.1 million ounces palladium equivalent inferred. Greenland Mines' project work includes geological review, mineral resource analysis, metallurgical and processing studies, environmental and hydro-geochemical investigation, Arctic logistics planning, and stakeholder engagement in Greenland.

The company's natural resources activities are organized around advancing Skaergaard as a multi-metal project. Public updates describe work with geological, metallurgical, mine engineering, environmental, and processing specialists. The company has also reported participation by Greenland Mines and Major Precious Greenland A/S in industry and business organizations connected to raw materials, Greenlandic commerce, and critical-minerals supply chains.

The Cell and Gene Therapy division reflects Greenland Mines' continuing biotechnology assets from its prior corporate identity. Company materials describe Klotho-related technology and KLTO-202 as part of the division's ALS-focused program. Earlier company descriptions also referenced licensed generic drug and biosimilar biologics platforms and proprietary technologies involving melanocortin receptor-binding molecules and a gene therapy platform intended to introduce Klotho, a therapeutic protein, inside the body.

Greenland Mines Ltd. is incorporated in Delaware and headquartered in Charlotte, North Carolina. Its common stock trades on the Nasdaq Stock Market under the symbol GRML, and its warrants are identified under the symbol GRMLW. SEC records identify the company as an emerging growth company.